Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The leading professional organisation for medical oncology
Meet us in Paris to interact with key opinion leaders and learn first-hand about practice challenges and controversies in oncology
Online application is open until 3 July 2022
The most comprehensive series on gastrointestinal cancers – join this highly specialised discussion with top experts
Step out on stage and share your research with a LIVE audience from the Asia-Pacific region and beyond, on 2-4 December in Singapore.
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Stay up to date with the latest data in HER2+ breast cancer and join this real-time discussion with international experts
From World GI 2022:
TOPAZ-1 exploratory analysis suggests that adding durvalumab to gemcitabine plus cisplatin improves advanced biliary tract cancer outcomes irrespective of the primary tumour site
A focus on the latest research in targeting cancer microbiome
Safety and efficacy were evaluated in BRF117019, NCI-MATCH, CTMT212X2101, and supported by results in COMBI-d, COMBI-v, and BRF113928 studies
ESMO would like to thank the Iranian Society of Medical Oncology and Hematology (ISMOH) for providing translation in the Persian language
ESMO would like to thank the Iranian Society of Medical Oncology and Hematology (ISMOH) for providing translation in the Persian language
ESMO has announced today the results of its Executive Board elections following the closure of the voting system on Monday 27 June 2022.
Findings of 4 years follow-up from the CheckMate 142 study
Final survival results in EORTC 26951 and RTOG 9402 phase III studies with addition of procarbazine, lomustine, and vincristine to radiotherapy
New indication concerns the adjuvant treatment of adult patients with germline BRCA1/2 mutations who have HER2-negative, high risk early breast cancer
Findings from a population-level retrospective cohort study
In advanced pre-treated endometrial cancer, patient-reported outcomes support efficacy benefits of the combination therapy
Two studies investigate the value of molecular profiling in the management of ovarian and endometrial cancers
Data presented at the ESMO Gynaecological Cancers Congress 2022 confirm the vital role of national screening programmes and highlight the importance of local access
In this era of precision medicine, affordable profiling is essential
The role of PARP inhibitors features in a number of sessions at the ESMO Gynaecological Cancers Congress 2022
A translational analysis of the DAISY trial improves knowledge on the mechanisms of action of the antibody–drug conjugate
In the SASCIA trial, sacituzumab govitecan was associated with a higher incidence of adverse events and dose delays than treatment of physician’s choice in patients with HER2-negative breast cancer at high risk of relapse, but dose reductions occurred with a similar frequency in both arms
Results from the VIOLETTE trial also suggest that mutation status may influence response to each agent
Two studies hint at a lack of effect of palbociclib on ovarian function and demonstrate similar reduced recurrence with abemaciclib regardless of menopausal status
Safety and efficacy were evaluated in BRF117019, NCI-MATCH, CTMT212X2101, and supported by results in COMBI-d, COMBI-v, and BRF113928 studies
Findings of 4 years follow-up from the CheckMate 142 study
Final survival results in EORTC 26951 and RTOG 9402 phase III studies with addition of procarbazine, lomustine, and vincristine to radiotherapy
New indication concerns the adjuvant treatment of adult patients with germline BRCA1/2 mutations who have HER2-negative, high risk early breast cancer
Findings from a population-level retrospective cohort study
Evidence for efficacy is based on the results from the ELARA study
The risk of ocular toxicity, including risk of severe visual loss and need for monitoring in paediatric patients treated with crizotinib
Data for 32 countries in this region reflect important underlying sociodemographic changes
Findings from a phase III ANCHOR study
The ESMO World Congress on Gastrointestinal Cancer, the annual event dedicated to the presentation and discussion of new findings in GI cancer treatment, research and care, will be held as a fully onsite event in Barcelona, Spain, from 29 June to 2 July 2022.
Data from two large cancer centres in the United States have shown that the COVID-19 pandemic caused substantial disruption to clinical trials for cancer treatment and care.
The ESMO Gynaecological Cancers Congress 2022, the annual event dedicated to improving the practice of gynaecological cancers specialists worldwide, will provide insights into the latest treatments, biology and biomarkers of ovarian, uterine, cervical and rare cancers.
The evidence-based tool is designed to help interpret data from a heterogeneous research landscape
The ESMO Breast Cancer Congress 2022, the annual event dedicated to advancing the science, disseminating education and improving the practice of breast cancer specialists worldwide, will focus this year on integrating translational research for innovative clinical practice.
A consensus reached by a lung clinical community within the International Cancer Benchmarking Partnership (ICBP), presented at the ELCC, 30 March – 2 April 2022, has highlighted international disparities in management and outcomes of patients with lung cancer in high-income countries, and has provided a roadmap of key actions that should be taken to homogenise practices, help enable earlier diagnosis and offer equitable access to care.
More than half of patients diagnosed with advanced non-small cell lung cancer (NSCLC) undergo biomarker testing, and this figure has increased over the last five years, reveal real-world data from a Spanish national registry study reported at the European Lung Cancer Congress (ELCC), 30 March-2 April 2022.
The European Lung Cancer Congress 2022 (ELCC), the annual event dedicated to advancing the science, disseminating education and improving the practice of lung cancer specialists worldwide, will be held as a virtual meeting.
Original data presentations by the authors of the OlympiA and PEARLS/KEYNOTE-091 trials will be followed by critical analysis and discussion with a panel of renowned experts.
ESMO has announced today the results of its Executive Board elections following the closure of the voting system on Monday 27 June 2022.
ESMO has announced today that the 2022 ESMO Breast Cancer Award is presented to Sibylle Loibl for her exceptional contribution to clinical research in breast cancer.
In light of the challenging situation in Prague due to the ongoing arrival of refugees from Ukraine
ESMO expresses profound sadness about the unfolding tragedy in Ukraine and the suffering of people
The 2022 ESMO Heine H. Hansen Award is conferred on Fred R. Hirsch for his lifelong outstanding contribution to lung cancer research
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
Who will be the next ESMO Awardees? Submit your nominations before 9 March.
ESMO has announced today that the 2022 ESMO TAT Honorary Award is presented to Lesley K Seymour
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Spain
Switzerland
Czech Republic
France
Republic of Singapore
Portugal
Switzerland
Republic of Singapore
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
Take the chance to grow as a clinician-scientist and to explore research in oncology: submit your application by 19 June 2022!
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
